The impact of practice guidelines on prescribing patterns of nondepolarizing neuromuscular blocking agents.
Guidelines for selecting nondepolarizing neuromuscular blocking agents (NNMBAs) were developed and implemented by an interdisciplinary team for use in our intensive care units. They suggest pancuronium as the drug of choice if the patient does not have renal insufficiency and is hemodynamically stable. If either of these criteria is not met and hepatic function is normal, vecuronium is recommended. Atracurium is reserved for patients not meeting either criterion. A 12-month retrospective chart review was performed for 24 patients 18 years of age or older who received continuous infusion of an NNMBA beginning 7 months after the guidelines were implemented. Before the guidelines, atracurium, vecuronium, and pancuronium were prescribed for 68% (17), 24% (6), and 8% (2) of patients, respectively. Their use was inappropriate based on organ function and hemodynamic stability in 88% (15), 83% (5), and 0% of patients, respectively. After guideline implementation, atracurium, vecuronium, and pancuronium were prescribed for 33% (8), 21% (5), and 46% (11) of patients, respectively, and use was inappropriate in 38% (3), 60% (3), and 0% of patients, respectively. Overall, the prevalence of inappropriate NNMBA selection decreased from 80% (20) to 25% (6). Further analysis is necessary to determine the associated pharmacoeconomic impact of decreased inappropriate NNMBA prescribing.
College of Pharmacy, University of Minnesota, Minneapolis, USA.
S J
SJ
Tschida
L L
LL
Hoey
K
K
Vance-Bryan
D001279:Atracurium / Q000627:therapeutic use; D004363:Drug Utilization; D005260:Female; D006745:Hospital Bed Capacity, 300 to 499; D006784:Hospitals, Teaching; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D008910:Minnesota; D003473:Neuromuscular Nondepolarizing Agents / Q000627:therapeutic use*; D010197:Pancuronium / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D014673:Vecuronium Bromide / Q000627:therapeutic use
D003473:Neuromuscular Nondepolarizing Agents; D001279:Atracurium; D014673:Vecuronium Bromide; D010197:Pancuronium